Literature DB >> 660491

Tissue culture cytotoxicity assay for cyclophosphamide metabolites in rat body fluids.

F A Weaver, A R Torkelson, W A Zygmunt, H P Browder.   

Abstract

An in vitro cytotoxicity assay for cyclophosphamide metabolites in rat body fluids is described. Of the two tissue culture tumor cell lines employed, the Walker-256 rat carcinosarcoma was more sensitive to metabolite levels than the L-1210 mouse lymphocytic leukemia. The Walker-256 system detected cyclophosphamide metabolite levels two orders of magnitude lower than the commonly used 4-(p-nitrobenzyl)pyridine analytical procedure.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 660491     DOI: 10.1002/jps.2600670738

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

Review 1.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  L B Grochow; M Colvin
Journal:  Clin Pharmacokinet       Date:  1979 Sep-Oct       Impact factor: 6.447

2.  Bioactivation of dapsone to a cytotoxic metabolite: in vitro use of a novel two compartment system which contains human tissues.

Authors:  R J Riley; P Roberts; M D Coleman; N R Kitteringham; B K Park
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

3.  Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration.

Authors:  F D Juma; H J Rogers; J R Trounce
Journal:  Br J Clin Pharmacol       Date:  1979-09       Impact factor: 4.335

4.  Distribution and pharmacokinetics of cyclophosphamide in the rat.

Authors:  M R Talha; H J Rogers; J R Trounce
Journal:  Br J Cancer       Date:  1980-01       Impact factor: 7.640

5.  A bioassay for cyclophosphamide in blood, lung and tumour.

Authors:  A C Begg; K A Smith
Journal:  Br J Cancer       Date:  1984-01       Impact factor: 7.640

6.  The effect of radiosensitizers on the pharmacokinetics of melphalan and cyclophosphamide in the mouse.

Authors:  M Hinchliffe; N J McNally; M R Stratford
Journal:  Br J Cancer       Date:  1983-09       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.